These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9717817)

  • 1. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.
    Beattie GJ; Smyth JF
    Clin Cancer Res; 1998 Aug; 4(8):1899-902. PubMed ID: 9717817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
    Macaulay VM; O'Byrne KJ; Saunders MP; Braybrooke JP; Long L; Gleeson F; Mason CS; Harris AL; Brown P; Talbot DC
    Clin Cancer Res; 1999 Mar; 5(3):513-20. PubMed ID: 10100701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
    Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
    Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
    Parsons SL; Watson SA; Steele RJ
    Eur J Surg Oncol; 1997 Dec; 23(6):526-31. PubMed ID: 9484924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Batimastat. BB 94, collagenase inhibitors-1.
    Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
    Planting A; van der Gaast A; Schöffski P; Bartkowski M; Verheij C; Noe D; Ferrante K; Verweij J
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):136-42. PubMed ID: 15592721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
    Talbot DC; Brown PD
    Eur J Cancer; 1996 Dec; 32A(14):2528-33. PubMed ID: 9059343
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
    Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ
    Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
    Low JA; Johnson MD; Bone EA; Dickson RB
    Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
    Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M; Cassidy J; Johnson J; Morrison R; Devlin M; Blackey R; Owen S; Choi L; Twelves C
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):39-46. PubMed ID: 15368080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
    Eskens FA; Levitt NC; Sparreboom A; Choi L; Mather R; Verweij J; Harris AL
    Clin Cancer Res; 2000 Feb; 6(2):431-3. PubMed ID: 10690520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
    Corbel M; Caulet-Maugendre S; Germain N; Molet S; Lagente V; Boichot E
    J Pathol; 2001 Apr; 193(4):538-45. PubMed ID: 11276015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
    Brown PD
    Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
    Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.